Key result
A recombinant VP6 immunoassay detected increased antibody reactivity in convalescent sera from GBR-infected patients (P=0.0084), with very low seroprevalence (<1%) observed in the US and Switzerland.
Population
Patients infected with the ADRV strain of group B rotavirus in China, 423 Maryland residents, 129 additional…
Design
Cross-sectional
Follow-up
up to >1 year after infection
Authors
Loading...
VP6 immunoassay aids GBR serology research; leaves open clinical testing role given <1% seroprevalence in tested populations.
Cross-Sectional
Yes
p-value: p=0.0084
A highly sensitive solid-phase immunoassay using recombinant VP6 can detect group B rotavirus antibodies, revealing rare seropositivity in older US populations.
Eiden et al. (1994) conducted a cross-sectional in Group B rotavirus infection. Group B rotavirus infection vs. Early infection sera / unexposed populations was evaluated on Increased reactivity with recombinant VP6 in convalescent-phase sera (p=0.0084). A recombinant VP6 immunoassay detected increased antibody reactivity in convalescent sera from GBR-infected patients (P=0.0084), with very low seroprevalence (<1%) observed in the US and Switzerland.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: